These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effects of marijuana on aqueous humor dynamics in a glaucoma patient. Zhan GL; Camras CB; Palmberg PF; Toris CB J Glaucoma; 2005 Apr; 14(2):175-7. PubMed ID: 15741823 [No Abstract] [Full Text] [Related]
3. Neuroprotection: is it already applicable to glaucoma therapy? Ritch R Curr Opin Ophthalmol; 2000 Apr; 11(2):78-84. PubMed ID: 10848224 [TBL] [Abstract][Full Text] [Related]
4. Is neuroprotection a viable therapy for glaucoma? Weinreb RN; Levin LA Arch Ophthalmol; 1999 Nov; 117(11):1540-4. PubMed ID: 10565524 [TBL] [Abstract][Full Text] [Related]
5. [Neuroprotection in glaucoma. What is the current status?]. Haefliger IO; Pellanda N; Fleischhauer JC; Gekkieva M; Flammer J Ophthalmologe; 2001 Jun; 98(6):564-7. PubMed ID: 11450482 [No Abstract] [Full Text] [Related]
6. [Neuro-hormonal regulation of aqueous humor dynamics as the basis of glaucoma pharmacotherapy. Part II - Aqueous humor outflow]. Terelak-Borys B; Liberek I Klin Oczna; 2007; 109(1-3):64-7. PubMed ID: 17687917 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotective Strategies in Glaucoma. Gossman CA; Christie J; Webster MK; Linn DM; Linn CL Curr Pharm Des; 2016; 22(14):2178-92. PubMed ID: 26818878 [TBL] [Abstract][Full Text] [Related]
9. Discovery of novel inhibitors for the treatment of glaucoma. Cholkar K; Trinh HM; Pal D; Mitra AK Expert Opin Drug Discov; 2015 Mar; 10(3):293-313. PubMed ID: 25575654 [TBL] [Abstract][Full Text] [Related]
10. Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Neufeld AH Surv Ophthalmol; 1999 Jun; 43 Suppl 1():S129-35. PubMed ID: 10416755 [TBL] [Abstract][Full Text] [Related]
11. Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives. Roberti G; Tanga L; Michelessi M; Quaranta L; Parisi V; Manni G; Oddone F Int J Mol Sci; 2015 Nov; 16(12):28401-17. PubMed ID: 26633368 [TBL] [Abstract][Full Text] [Related]
12. Should we treat the brain in glaucoma? Gupta N; Yücel YH Can J Ophthalmol; 2007 Jun; 42(3):409-13. PubMed ID: 17508036 [TBL] [Abstract][Full Text] [Related]
13. Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats. Levkovitch-Verbin H; Vander S; Melamed S J Glaucoma; 2011; 20(5):273-7. PubMed ID: 20577110 [TBL] [Abstract][Full Text] [Related]
14. Neuroprotective and intraocular pressure-lowering effects of (-)Delta9-tetrahydrocannabinol in a rat model of glaucoma. Crandall J; Matragoon S; Khalifa YM; Borlongan C; Tsai NT; Caldwell RB; Liou GI Ophthalmic Res; 2007; 39(2):69-75. PubMed ID: 17284931 [TBL] [Abstract][Full Text] [Related]
15. Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma. Pirhan D; Yüksel N; Emre E; Cengiz A; Kürşat Yıldız D Curr Eye Res; 2016; 41(1):59-69. PubMed ID: 25658983 [TBL] [Abstract][Full Text] [Related]
16. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Osborne NN; Ugarte M; Chao M; Chidlow G; Bae JH; Wood JP; Nash MS Surv Ophthalmol; 1999 Jun; 43 Suppl 1():S102-28. PubMed ID: 10416754 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model. Can N; Catak O; Turgut B; Demir T; Ilhan N; Kuloglu T; Ozercan IH Drug Des Devel Ther; 2015; 9():2819-29. PubMed ID: 26082612 [TBL] [Abstract][Full Text] [Related]